Retatrutide (RT) 40 mg/vial — 10 Vials/Kit
Retatrutide, commonly abbreviated RT and identified by the development code LY3437943 (LY-3437943), is an investigational peptide developed by Eli Lilly. It is designed as a triple hormone-receptor agonist, activating the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly’s current development program is investigating retatrutide in several metabolic and cardiometabolic conditions.
For the configuration you specified, 40 mg/vial × 10 vials/kit = 400 mg nominal total content per kit.
Important product-page correction: because you requested 40 mg/vial, the Strength field should be 40 mg/vial, not 10 mg/vial.
📋 Product Identification
| 🏷️ Product Field | 🔬 Details |
|---|---|
| Product Name | Retatrutide |
| Development Code | LY3437943 / LY-3437943 |
| Strength | 40 mg/vial |
| Packaging | 10 vials/kit |
| Total Kit Content | 400 mg nominal retatrutide |
| CAS No. | 2381089-83-2 |
| Alternative Name | LY-3437943 / LY3437943 |
| Product Type | Investigational peptide / research compound |
| Abbreviation | RT / Reta |
| Molecular Classification | GIP/GLP-1/glucagon receptor triple agonist |
| Developer | Eli Lilly and Company |
| Primary Research Field | Metabolic and cardiometabolic research |
| Number of Vials | 10 |
| Nominal Content per Vial | 40 mg |
| Nominal Total Kit Content | 400 mg |
PubChem lists retatrutide, LY-3437943, and LY3437943 among the compound’s synonyms and lists 2381089-83-2 as an identifier.
🧬 What Is Retatrutide?
Retatrutide is an investigational peptide being developed by Eli Lilly. Its distinguishing characteristic is that a single molecule acts at three hormone receptors:
- 🧬 GIP receptor
- 🧬 GLP-1 receptor
- 🧬 Glucagon receptor
Lilly describes LY3437943 as a biologic entity that acts as a triagonist at these three receptors.
This triple-receptor activity is the central scientific feature of retatrutide. Researchers are investigating how simultaneously activating these pathways may affect body weight, glucose regulation, energy metabolism and complications associated with obesity.
Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist. In clinical trials, it has been administered as a once-weekly subcutaneous injection.
The informal term “GLP-3” should not be used as the scientific name for this compound. Lilly specifically explains that “GLP-3” is an inaccurate informal label; triple agonist is the more appropriate description.
🔬 How Retatrutide Works
1. GIP receptor activity
GIP, or glucose-dependent insulinotropic polypeptide, is an incretin hormone involved in metabolic signaling.
Researchers are interested in GIP receptor activity because the pathway participates in glucose and energy metabolism.
2. GLP-1 receptor activity
GLP-1, or glucagon-like peptide-1, is another important metabolic hormone.
GLP-1 receptor signaling has been extensively investigated in relation to glucose regulation, appetite, gastrointestinal physiology and body-weight regulation.
3. Glucagon receptor activity
Glucagon has important roles in glucose and energy metabolism.
Retatrutide’s glucagon-receptor activity is an important part of its pharmacological profile and helps distinguish it from compounds that target only GLP-1 or GLP-1/GIP pathways.
🧬 Triple-receptor concept
The mechanism can therefore be summarized as:
GIP + GLP-1 + Glucagon → Retatrutide
This three-pathway mechanism is the principal reason retatrutide is being studied as a distinct class of investigational metabolic therapy.
⚖️ Research Uses of Retatrutide
Retatrutide is being investigated in several areas rather than being limited to one research indication.
⚖️ 1. Obesity and Weight Research
Obesity is one of the major areas in the retatrutide clinical-development program.
Lilly’s Phase 3 TRIUMPH program has evaluated retatrutide in adults with obesity or overweight. TRIUMPH-1, for example, studied participants with obesity or overweight and examined efficacy and safety, including subsets involving knee osteoarthritis and obstructive sleep apnea.
Lilly subsequently reported positive Phase 3 results from several trials. These findings are clinical-trial results, rather than a guarantee that an individual will experience the same outcome.
🩸 2. Type 2 Diabetes Research
Retatrutide is also being studied in people with type 2 diabetes.
The TRIUMPH-2 study evaluated adults with type 2 diabetes and obesity or overweight, while other TRANSCEND-T2D studies are investigating retatrutide against placebo or other treatments.
Research has included outcomes such as:
- HbA1c
- Body weight
- Glycemic control
- Safety and tolerability
❤️ 3. Cardiovascular and Renal Research
Another major research area involves cardiovascular and kidney outcomes.
The TRIUMPH-3 study evaluated retatrutide in participants with obesity and established cardiovascular disease.
Lilly’s broader development program also includes a large Phase 3 cardiovascular/renal outcomes study examining cardiovascular and kidney outcomes in adults living with obesity.
🦴 4. Knee Osteoarthritis Research
Retatrutide has also been investigated in adults with obesity or overweight and knee osteoarthritis.
TRIUMPH-4 specifically examined once-weekly retatrutide in this population.
This research is particularly relevant because excess body weight and mechanical loading can contribute to knee-joint problems.
😴 5. Obstructive Sleep Apnea Research
Obesity-associated obstructive sleep apnea (OSA) is another area of investigation.
Lilly’s development program includes retatrutide research involving moderate-to-severe OSA in adults with obesity or overweight.
🧬 6. Metabolic Liver Disease Research
Retatrutide is also being investigated for metabolic dysfunction-associated steatotic liver disease (MASLD).
This expands the research program beyond weight and glucose into metabolic complications associated with obesity.
🧍 7. Chronic Low-Back Pain Research
Lilly’s current pipeline also identifies chronic low-back pain as an area being investigated with retatrutide.
⭐ Scientific Advantages of Retatrutide
The principal research advantage of retatrutide is its multi-receptor pharmacology.
| 🔬 Feature | 📖 Research Significance |
|---|---|
| 🧬 Triple agonism | One molecule activates GIP, GLP-1 and glucagon receptors. |
| ⚖️ Weight research | Being evaluated extensively in obesity and overweight populations. |
| 🩸 Glucose research | Being investigated for effects on HbA1c and glycemic control. |
| ❤️ Cardiovascular research | Studied in people with obesity and established cardiovascular disease. |
| 🧬 Liver research | Investigated in MASLD. |
| 😴 OSA research | Studied in obesity-associated obstructive sleep apnea. |
| 🦴 Osteoarthritis research | Investigated in obesity/overweight with knee osteoarthritis. |
| 🧪 Novel mechanism | Provides researchers with a model for studying simultaneous incretin and glucagon signaling. |
| 📚 Broad clinical program | Multiple Phase 3 studies cover different populations and outcomes. |
These should be understood as research advantages, not guaranteed therapeutic benefits.
📦 RT 40 mg/vial — 10 Vials/Kit
The requested configuration contains:
40 mg × 10 vials = 400 mg nominal total content
| 📦 Package Component | Quantity |
|---|---|
| Retatrutide per vial | 40 mg |
| Number of vials | 10 |
| Total nominal content | 400 mg |
| Development code | LY3437943 |
| Short code | RT |
The 40 mg/vial designation describes the nominal amount represented by each vial. It should not be interpreted as a recommended clinical dose.
In particular, a product’s vial strength and a clinical trial’s dose are separate concepts. Current Lilly clinical trials have evaluated defined study doses and dose-escalation schedules; a 40 mg vial specification does not establish an appropriate human dose.
🧪 Product Quality and Laboratory Information
For a professional research-product listing, analytical information should only be published when supported by documentation from the actual manufacturer or supplier.
Depending on your supplier’s documentation, a product page may contain:
- 🔬 Peptide purity
- 🧪 Certificate of Analysis (CoA)
- 🧬 Peptide identity
- ⚗️ Analytical testing
- 📦 Batch/Lot number
- 🧫 Endotoxin testing
- 💧 Residual moisture
- 📅 Manufacturing date
- ⏳ Retest/expiration date
- 🧪 Formulation information
Do not automatically claim that a product is “99% pure,” “GMP grade,” “sterile,” “pharmaceutical grade,” or “clinically proven” unless the relevant documentation actually supports those claims.
This is particularly important with retatrutide because Lilly warns that products claiming to contain retatrutide outside its clinical-trial system may contain incorrect quantities, impurities, contaminants or even a different ingredient.
📊 Detailed Product Specification
| 🏷️ Specification | 🔬 Detailed Description |
|---|---|
| Product Name | Retatrutide |
| Development Code | LY3437943 |
| Alternative Code | LY-3437943 |
| Short Name | RT |
| CAS Number | 2381089-83-2 |
| Strength | 40 mg/vial |
| Packaging | 10 vials/kit |
| Total Kit Content | 400 mg nominal |
| Product Type | Investigational peptide / research compound |
| Molecular Class | GIP/GLP-1/glucagon receptor triple agonist |
| Developer | Eli Lilly and Company |
| Primary Research Area | Metabolic and cardiometabolic research |
| Research Areas | Obesity, overweight, type 2 diabetes, cardiovascular/renal outcomes, MASLD, OSA, knee osteoarthritis and chronic low-back pain |
| Clinical Development | Phase 3 |
| Clinical Administration Studied | Once-weekly subcutaneous administration |
| Number of Vials | 10 |
| Nominal Amount per Vial | 40 mg |
| Nominal Total per Kit | 400 mg |
| Regulatory Status | Investigational; not FDA-approved |
Lilly’s current information states that retatrutide remains investigational and is not currently approved by the FDA.
⚠️ Regulatory Status
Retatrutide is not currently FDA-approved. Lilly states that it remains an investigational medication and that its safety and efficacy are still being evaluated in clinical trials.
Therefore, a product listing should avoid claims such as:
❌ FDA-approved weight-loss medication
❌ Guaranteed weight loss
❌ Guaranteed diabetes treatment
❌ Safe for everyone
❌ No side effects
❌ Approved prescription medicine
More appropriate terminology for an informational/research listing includes:
✅ Investigational peptide
✅ Research compound
✅ Triple GIP/GLP-1/glucagon receptor agonist
✅ Under clinical investigation
✅ Metabolic research compound
✅ Not currently FDA-approved
Lilly announced in July 2026 that it planned to submit a Biologics License Application for retatrutide to the FDA in Q1 2027, further confirming that it remains in the investigational stage at present.
Retatrutide (LY3437943), also known as RT, is an investigational GIP/GLP-1/glucagon triple receptor agonist developed by Eli Lilly. This product configuration contains 10 individual vials specified at 40 mg per vial, providing 400 mg of nominal total content per kit. Retatrutide is being investigated across metabolic and cardiometabolic research areas including obesity, type 2 diabetes, cardiovascular and renal outcomes, metabolic liver disease, obstructive sleep apnea and obesity-associated knee osteoarthritis. For legitimate research purposes; not currently FDA-approved for general public use.
- Retatrutide 40mg
- Retatrutide 40 mg vial
- Retatrutide LY3437943
- LY3437943 peptide
- LY-3437943
- RT 40mg
- Retatrutide 10 vial kit
- Retatrutide research peptide
- Retatrutide research compound
- GIP GLP-1 glucagon triple agonist
- Retatrutide metabolic research
- Retatrutide obesity research
- Retatrutide type 2 diabetes research
- Retatrutide 40mg/vial 10 vials
📌 Final Product Summary
RT 40 mg/vial × 10 vials/kit represents a nominal package configuration of 10 individual vials at 40 mg each, totaling 400 mg.
The compound is retatrutide, with development code LY3437943, alternative code LY-3437943, and CAS 2381089-83-2. Its defining pharmacological characteristic is activity at GIP, GLP-1 and glucagon receptors. It is currently being investigated in Phase 3 programs covering obesity, type 2 diabetes and several obesity-related metabolic and cardiometabolic conditions, but it remains an investigational medicine rather than an FDA-approved product.

